Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Josua Jordi
Co-founder and CEO
josua.jordi@eracal.ch

Message the company or request a 1:1 meeting here

The preclinical biotech startup EraCal Therapeutics Ltd. develops a novel anti-obesity drug with superior efficacy and tolerability compared to the standard of care in animal models. An ambitious team with world-class advisors leads the research around appetite modulation. EraCal’s phenotypic drug discovery platform is applicable to other indications. EraCal is a spin-off of the University of Zurich and Harvard University.

Executive Summary